Daratumumab or Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: An Indirect Comparison Based on Reconstructing Individual Patient Data from Kaplan-Meier Overall Survival Curves Using an Artificial-Intelligence Algorithm

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".